Pharmacological tools in endocannabinoid neurobiology

Current Topics in Behavioral Neurosciences

Volumn 1, Issue , 2009, Pages 87-110

  Mor, Marco ^a   Lodola, Alessio ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Anandamide Transport; FAAH inhibitors; MGL inhibitors; NAAA inhibitors

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; ENDOCANNABINOID; ENZYME INHIBITOR; LIGAND;

ANIMAL; ARTICLE; CHEMISTRY; CLASSIFICATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; NEUROBIOLOGY;

ANIMALS; CANNABINOIDS; ENDOCANNABINOIDS; ENZYME INHIBITORS; HUMANS; LIGANDS; NEUROBIOLOGY; RECEPTORS, CANNABINOID;

EID: 79952115220     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/978-3-540-88955-7_4     Document Type: Article

References (127)

1. Ahn K, Johnson DS, Fitzgerald LR et al. (2007) Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 46:13019-13030
2. Alexander JP, Cravatt BF (2005) Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol 12:1179-1187
3. Bari M, Battista N, Fezza F et al. (2006) New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem 6:257-268
4. 9-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 27:19902-19905
5. Beltramo M, Stella N, Calignano A et al. (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094-1097
6. 2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol 151:1061-1070
7. Bisogno T, Howell F, Williams G et al. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163:463-468
8. Bisogno T, Cascio MG, Saha B et al. (2006) Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 1761:205-212
9. Boger DL, Sato H, Lerner AE et al. (2000) Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 97:5044-5049
10. Boger DL, Miyauchi H, Du W et al. (2005) Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem 48:1849-1856
11. Bortolato M, Mangieri RA, Fu J et al. (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62:1103-1110
12. Brown AJ (2007) Novel cannabinoid receptors. Br J Pharmacol 152:567-575
13. De Petrocellis L, Melck D, Ueda N et al. (1997) Novel inhibitors of brain neuronal and basophilic anandamide amidohydrolase. Biochem Biophys Res Commun 231:82-88
14. Deutsch DG, Chin SA (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46:791-796
15. Deutsch DG, Lin S, Hill WA et al. (1997) Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun 3:217-221
16. Devane WA, Dysarz FA III, Johnson MR et al. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613
17. Di Marzo V, De Petrocellis L, Sepe N et al. (1996) Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J 316:977-984
18. Di Marzo V, Bisogno T, De Petrocellis L et al. (1999) Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 264:258-267
19. Di Marzo V, Bisogno T, De Petrocellis L et al. (2001) Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. Biochem Biophys Res Commun 281:444-451
20. Dinh TP, Carpenter D, Leslie FM et al. (2002a) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99:10819-10824
21. Dinh TP, Freund TF, Piomelli D (2002b) A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 31:149-158
22. Elsohly MA (2002) Chemical constituents of cannabis. In: Grotenherman F, Russo E (eds) Cannabis and cannabinoids. Pharmacology, toxicology and therapeutic potential. Haworth Press, Binghamton, NY
23. 2selectivity. Bioorg Med Chem Lett 18:1725-1729
24. Fegley D, Kathuria S, Mercier R et al. (2004) Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci USA 101:8756-8761
25. 2receptors. Mol Pharmacol 48:443-450
26. Fong TM, Guan XM, Marsh DJ et al. (2007) Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S, 2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[5-(trifluoromethyl) pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. J Pharmacol Exp Ther 321:1013-1022
27. Fowler CJ, Tiger G, Ligresti A et al. (2004) Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis: a difficult issue to handle. Eur J Pharmacol 492:1-11
28. Fowler CJ, Holt S, Nilsson O et al. (2005) The endocannabinoid signaling system: pharmacological and therapeutic aspects. Pharmacol Biochem Behav 81:248-262
29. Fu J, Gaetani S, Oveisi F et al. (2003) Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425:90-93
30. Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646-1647
31. Gardner A, Mallet PE (2006) Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. Eur J Pharmacol 530:103-106
32. 2) receptors. J Recept Signal Transduct Res 26:709-730
33. Ghafouri N, Tiger G, Razdan RK et al. (2004) Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br J Pharmacol 143:774-784
34. Giblin GM, O'Shaughnessy CT, Naylor A et al. (2007) Discovery of 2-[(2, 4-dichlorophenyl) amino]-N-[(tetrahydro-2H-pyran-4-yl) methyl]-4-trifluoromethyl)-5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J Med Chem 50:2597-2600
35. Glaser S, Abumrad N, Fatade F et al. (2003) Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci USA 100:4269-4274
36. Gobbi G, Bambico FR, Mangieri et al. (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102:18620-18625
37. 35S]Sch225336. J Biol Chem 281:28143-28151
38. 2) in rodents and primates. Br J Pharmacol 151:1262-1271
39. Gonsorek W, Lunn C, Fan X et al. (2000) Endocannabinoid 2-AG is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol 57:1045-1050
40. 2receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153:319-334
41. 2receptors. Br J Pharmacol 150:693-701
42. 2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96:14228-14233
43. 1). J Pharmacol Exp Ther 289:1427-1433
44. Hillard CJ, Shi L, Tuniki VR et al. (2007) Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase. J Mol Neurosci 33:18-24
45. Ho W-SV, Hillard CJ (2005) Modulators of endocannabinoid enzymic hydrolysis and membrane transport. In: Pertwee RG (ed) Cannabinoids. Handbook of experimental pharmacology. Springer, Heidelberg
46. Hohmann AG, Suplita RL, Bolton NM et al. (2005) An endocannabinoid mechanism for stressinduced analgesia. Nature 435:1108-1112
47. 1receptors with hypophagic effects in rats. Br J Pharmacol 152:805-814
48. Howlett AC, Barth F, Bonner TI et al. (2002) International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202
49. Huffman JW, Liddle J, Yu S et al. (1999) 3-(10, 10-Dimethylbutyl)-1-deoxy-D8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. BioorgMed Chem 7:2905-2914
50. 2receptor. J Pharmacol Exp Ther 296:420-425
51. 1cannabinoid antagonists: structureactivity relationships and potential therapeutic applications. Curr Top Med Chem 8:205-230
52. Jarrahian A, Manna S, Edgemond WS et al. (2000) Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. J Neurochem 74:2597-2606
53. Jayamanne A, Greenwood R, Mitchell VA et al. (2006) Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147:281-288
54. 2receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but not the release of b-hexosaminidase from skin slices in vitro. Life Sci 78:598-606
55. Karlsson M, Contreras JA, Hellman U et al. (1997) cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem 272:27218-27223
56. Kathuria S, Gaetani S, Fegley et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81
57. Khanolkar AD, Lu D, Ibrahim M et al. (2007) Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem 50:6493-6500
58. 2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J Pharmacol Sci 106:219-224
59. King AR, Duranti A, Tontini A et al. (2007) URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol 14:1357-1365
60. Koutek B, Prestwich GD, Howlett AC et al. (1994) Inhibitors of arachidonoyl ethanolamide hydrolysis. J Biol Chem 269:22937-22940
61. Kuster JE, Stevenson JI, Ward SJ et al. (1993) Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J Pharmacol Exp Ther 264:1352-1363
62. Labar G, Michaux C (2007) Fatty acid amide hydrolase: from characterization to therapeutics. Chem Biodivers 4:1882-1902
63. Labar G, Bauvois C, Muccioli GG et al. (2007) Disulfiram is an inhibitor of human purified monoacylglycerol lipase, the enzyme regulating 2-arachidonoylglycerol signaling. Chembiochem 23:1293-1297
64. Lambert D, Fowler CJ (2005) The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 48:1-29
65. Lichtman AH, Leung D, Shelton C et al. (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311:441-448
66. Lo Verme J, Fu J, Astarita G et al. (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67:15-19
67. Lodola A, Mor M, Hermann JC et al. (2005) QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation. Chem Commun (Camb) 35:4399-4401
68. Lodola A, Mor M, Rivara S et al. (2008) Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling. Chem Commun (Camb) 2:214-216
69. Lopez-Rodrguez ML, Viso A, Ortega-Gutierrez S et al. (2003) Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. J Med Chem 46:1512-1522
70. Lunn CA, Fine JS, Rojas-Triana A et al. (2006) A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 316:780-788
71. 2receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol 542:179-183
72. Maione S, De Petrocellis L, de Novellis V et al. (2007) Analgesic actions of N-arachidonoylserotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150:766-781
73. Makara JK, Mor M, Fegley D et al. (2005) Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8:1139-1141
74. Makara JK, Mor M, Fegley D et al. (2007) Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 10:134
75. Manera C, Benetti V, Castelli MP et al. (2006) Design, synthesis, and biological evaluation of new 1, 8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. J Med Chem 49:5947-5957
76. Martin BR, Wiley JL, Beletskaya I et al. (2006) Pharmacological characterization of novel watersoluble cannabinoids. J Pharmacol Exp Ther 318:1230-1239
77. McKinney MK, Cravat BF (2005) Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74:411-432
78. Mechoulam R (2005) Plant cannabinoids: a neglected pharmacological treasure trove. Br J Pharmacol 146:913-915
79. Mechoulam R, Peters M, Murillo-Rodriguez E et al. (2007) Cannabidiol-recent advances. Chem Biodivers 4:1678-1692
80. Mor M, Rivara S, Lodola A et al. (2004) Cyclohexylcarbamic acid 3'-or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modelling studies. J Med Chem 47:4998-5008
81. Muccioli GG (2007) Blocking the cannabinoid receptors: drug candidates and therapeutic promises. Chem Biodivers 4:1805-1827
82. Muccioli GG, Xu C, Odah E et al. (2007) Identification of a novel endocannabinoid-hydrolysing enzyme expressed by microglial cells. J Neurosci 27:2883-2889
83. Murineddu G, Lazzari P, Ruiu S et al. (2006) Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3 carboxamide. J Med Chem 49:7502-7512
84. 2cannabinoid receptor agonists with an analgesic action. Bioorg Med Chem 16:1111-1124
85. Okamoto Y, Wang J, Morishita J et al. (2007) Biosynthetic pathways of the endocannabinoid anandamide. Chem Biodivers 4:1842-1857
86. Ortar G, Ligresti A, De Petrocellis L et al. (2003) Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol 65:1473-1481
87. Pacher P, Batkay S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:390-462
88. Pavon FJ, Bilbao A, Hernández-Folgado L et al. (2006) Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole-LH 21. Neuropharmacology 51:358-366
89. 1receptors. Life Sci 76:1307-1324
90. Pertwee RG (2005b) Pharmacological action of cannabinoid. In: Pertwee RG (ed) Cannabinoids. Handbook of experimental pharmacology. Springer, Heidelberg
91. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873-884
92. Piomelli D (2005) The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 6:672-679
93. Piomelli D, Tarzia G, Duranti A et al. (2006) Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12:21-38
94. 2selective ligands. Br J Pharmacol 153:335-346
95. 1receptor. Mol Pharmacol 68:1484-1495
96. Rinaldi-Carmona M, Barth F, Heaulme M et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244
97. 2cannabinoid receptor. J Pharmacol Exp Ther 284:644-650
98. 1receptor. Br J Pharmacol 152:565-566
99. 1cannabinoid receptor. J Pharmacol Exp Ther 306:363-370
100. Russo R, Lo Verme J, La Rana G et al. (2007) The fatty-acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neurophatic pain after oral administration. J Pharmacol Exp Ther 322:236-242
101. Ryberg E, Larsson N, Sjögren S et al. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092-1101
102. Saario SM, Laitinen JT (2007a) Monoglyceride lipase as an enzyme hydrolyzing 2-arachidonoylglycerol. Chem Biodivers 4:1903-1913
103. Saario SM, Laitinen JT (2007b) Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. Basic Clin Pharmacol Toxicol 101:287-293
104. Saario SM, Savinainen JR, Laitinen JT et al. (2004) Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem Pharmacol 67:1381-1387
105. Saario SM, Salo OM, Nevalainen T et al. (2005) Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chem Biol 12:649-656
106. Sink KS, McLaughlin PJ, Wood JA et al. (2008) The novel cannabinoid CB(1) receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33:946-955
107. Song ZH, Bonner TI (1996) A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol 49:891-896
108. Sugiura T, Kishimoto S, Oka S et al. (2006) Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 45:405-446
109. Suplita RL 2nd, Gutierrez T, Fegley D et al. (2006) Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology 50:372-379
110. 1receptor antagonist. Eur J Pharmacol 487:213-221
111. 2receptor antagonist. Br J Pharmacol 146:917-926
112. 1cannabinoid receptor as determined through the use of conformationally constrained analogs. AAPS J 8:E665-E671
113. Tonidandel L, Tarzia G, Antonietti F et al. (2006) On the formation of [H3C-S-S-CH3]+* ions from the bis(dimethylthio) mercury molecular ion. Rapid Commun Mass Spectrom 20:3154-3158
114. Tsuboi K, Hilligsmann C, Vandevoorde S et al. (2004) N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase. Biochem J 379(Pt 1):99-106
115. Tsuboi K, Sun YX, Okamoto Y et al. (2005) Molecular characterization of N-acylethanolaminehydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem 280:11082-11092
116. Tsuboi K, Takezaki N, Ueda N (2007) The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers 4:1914-1925
117. Ueda N, Yamanaka K, Terasawa Y et al. (1999) An acid amidase hydrolyzing anandamide as an endogenous ligand for cannabinoid receptors. FEBS Lett 454:267-270
118. Ueda N, Yamanaka K, Yamamoto S (2001) Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem 276:35552-35557
119. Valenzano KJ, Tafesse L, Lee G et al. (2005) Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48:658-672
120. Vandevoorde S (2008) Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors. Curr Top Med Chem 8:247-267
121. Vandevoorde S, Fowler CJ (2005) Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate. Br J Pharmacol 145:885-893
122. Wang J, Okamoto Y, Morishita J et al. (2006) Functional analysis of the purified anandamidegenerating phospholipase D as a member of the metallo-beta-lactamase family. J Biol Chem 281:12325-12335
123. Wei BQ, Mikkelsen TS, McKinney MK et al. (2006) A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 281:36569-36578
124. 2receptor agonists. Curr Med Chem 14:917-936
125. Woods SC (2007) The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. JAAPA 20(Suppl Endocannabinoid):7-10
126. 2receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol 153:390-401
127. Zhang D, Saraf A, Kolasa T et al. (2007) Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology 52:1095-1105